BioCentury
ARTICLE | Clinical News

Cerus reports Phase III data

August 22, 2000 7:00 AM UTC

CERS and partner Baxter Healthcare (BAX) reported data from a 103-patient Phase III trial in Europe in which CERS's Intercept Platelet System (IPS) provided platelet transfusion support consistent with medical practice. Intercept is a platelet pathogen inactivation system using psoralen S-59 light-activated compound. The system is designed to protect against transmission of infectious diseases through blood transfusions. Based on the results, the partners plan to file for European marketing approval. ...